[MARKET ANALYSIS] European bourses broadly firmer as US-Iran strikes pause, AZN LN slumps following reports of a potential BMY merger
- European bourses start the week broadly higher across the board, helped by the announcement by US President Trump over the weekend that he cancelled strikes on Iran at the request of Tehran and other Middle East countries, subject to the immediate opening of the Strait of Hormuz. Energy benchmarks have dropped as a result, with the broader Energy sector lower by 1.4%. Elsewhere, EZ and UK Manufacturing PMIs were ticked lower. Within the broader EZ release, S&P stated that new work inflows remain worryingly weak and that the manufacturing economy is not quite as healthy as the headline figure (51.9) suggests.
- Sectors highlight the positive bias. Autos is the clear outperformer, followed by Travel & Leisure and Consumer Products & Services. Outside of Energy, Food, Beverages & Tobacco and Health Care are the sector laggards.
- On a quiet day of European earnings, there have been a lot of M&A stories. Starting with the biggest story of the day, the FT reported that AstraZeneca have been in talks with Bristol Myers Squibb on a potential merger, which would be the biggest pharma deal of all time. Shares of Astra have slumped by over 7% at one point, with BMY shares up over 8% pre-market. However, the merger will come under tough antitrust scrutiny, according to analysts at BMO, due to the significant business overlap between the Co.'s cancer drug portfolios.
- In other M&A moves: Prysmian (-1.8%), acquires Atkore for USD 3.8bln; BMPS (+0.2%), considering the acquisition of Banco BPM according to the FT; Ageas (+2.4%), sells its minority stake in Eqita for c. USD 1.2bln; Holcim (-1.7%), sells its Philippines business for at least USD 807mln.
- US equity futures are higher, given the broader risk-on tone. Outside of the AZN-BMY story, market-moving US equity stories have been light. ZDnet reported that NVIDIA(NVDA) GeForce RTX 50 series graphics card prices in South Korea are rising by up to 30% from August, driven by higher GDDR7 memory costs and TSMC (TSM) advanced process wafer price increases.
The session splits into two distinct narratives. On the macro side, risk premia built around a US-Iran escalation have unwound on the strike pause, the classic sequence in Gulf tension episodes: crude and freight risk deflate first, energy lags while cyclicals and travel lead, and the move stays hostage to the condition attached, here the immediate reopening of the Strait of Hormuz, which makes tanker traffic and insurance rates the tell rather than the headline itself. The dominant idiosyncratic story is the reported AstraZeneca-Bristol Myers Squibb merger approach, which if genuine would be the largest pharmaceutical combination on record. The tape reaction follows the established pattern for large all-share or cash-and-stock approaches: target up, acquirer down sharply, with the acquirer's discount reflecting leverage, integration risk, and, in this case, the flagged antitrust problem, since overlapping oncology franchises are precisely the area where competition authorities have historically demanded divestitures or blocked combinations. Large pharma tie-ups have a mixed completion record; several announced mega-deals in the sector have collapsed or been restructured under regulatory or shareholder pressure, so the arb spread here will price completion risk heavily from the outset. Confirmation or denial from either company is the first follow-on, then any early commentary from US, UK, and EU competition officials, and the read-across to other large-cap pharma names where consolidation logic applies. The quieter European tape (soft PMI internals beneath an unchanged headline, thin earnings) means the index-level calm understates the single-stock dispersion on the day.